Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | DAB2IP | Q5VWQ8 | 1/20 | 1.00 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.84 |
| ▸ | SHBG | P04278 | 2/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12027476 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL6010005 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL13123058 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL29565170 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL15491309 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL225052 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL4206797 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL2617357 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL3868013 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL5025553 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023234790-A1 | APPLICATION OF HYDROGEN PEROXIDE AND 17β-ESTRADIOL AND ITS METABOLITES AS BIOMARKERS IN A METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASES IN VITRO | GDANSKI UNIWERSYTET MEDYCZNY (PL) | 2023-12-07 | — | — | WO | claimed |
| US-20210379087-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2021-12-09 | — | — | US | claimed |
| EP-3643305-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | Universität für Bodenkultur Wien (AT) | 2020-04-29 | — | — | EP | claimed |
| CN-109839451-A | Rapid analysis method while perfluorinated compound, phenolic compound and estrogen in a kind of blood | 复旦大学 | 2019-06-04 | — | — | CN | claimed |
| US-7951890-B2 | Using epichlorohydrin to form gel; pulverization; mixing with buffer solution and hydrolases; stirring; centrifuging | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-31 | — | — | US | claimed |
| US-20090169526-A1 | BMP-6 ESTROGEN RESPONSIVE ELEMENT AND METHODS OF USE THEREOF | WYETH | 2009-07-02 | — | — | US | claimed |
| CN-100406015-C | Estradiol metabolites for the treatment of pulmonary hypertension | UNIV PITTSBURGH (US) | 2008-07-30 | — | — | CN | claimed |
| CN-101056643-A | Long acting injectable crystal formulations of estradiol metabolites and methods of using same | PR PHARMACEUTICALS INC (US) | 2007-10-17 | — | — | CN | claimed |
| EP-1829529-A1 | Controlled release compositions of estradiol metabolites | PR Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| EP-1507514-B1 | CONTROLLED RELEASE COMPOSITIONS OF ESTRADIOL METABOLITES | PR PHARMACEUTICALS INC (US) | 2007-02-14 | — | — | EP | claimed |
| CN-1571672-A | Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders | UNIV PITTSBURGH (US) | 2005-01-26 | — | — | CN | claimed |
| EP-0923376-B1 | USE OF STEROIDS FOR TREATMENT OF ASTHMA AND AIRWAY DISEASES | AMRAD OPERATIONS PTY LTD (AU) | 2004-11-03 | — | — | EP | claimed |
| WO-2003092585-A2 | CONTROLLED RELEASE COMPOSITIONS OF ESTRADIOL METABOLITES | PR PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | claimed |
| EP-1330467-A2 | MODIFIED, HYDROXY-SUBSTITUTED AROMATIC STRUCTURES HAVING CYTOPROTECTIVE ACTIVITY | WASHINGTON UNIVERSITY (US) | 2003-07-30 | — | — | EP | claimed |
| US-20020103178-A1 | Modified, hydroxy-substituted aromatic structures having cytoprotective activity | WASHINGTON UNIVERSITY | 2002-08-01 | — | — | US | claimed |
| CN-1354184-A | Method for synthesizing 2-methoxyestradiol and application of its product | LIAONING WEIXING BIOLOG PRODUC (CN) | 2002-06-19 | — | — | CN | claimed |
| WO-2002036605-A2 | ESTRONE-DERIVATIVES HAVING CYTOPROTECTIVE ACTIVITY | WASHINGTON UNIVERSITY (US) | 2002-05-10 | — | — | WO | claimed |
| US-5962445-A | Treatment of asthma and airway diseases | AMRAD OPERATIONS PTY LTD. (AU) | 1999-10-05 | — | — | US | claimed |
| CN-1218401-A | Treatment of asthma and airway diseases | AMRAD OPERATIONS PTY LTD (AU) | 1999-06-02 | — | — | CN | claimed |
| WO-1999001142-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANGIOSTATIC STEROID COMBINED WITH A HYALURONAN | HYAL PHARMACEUTICAL CORPORATION (CA) | 1999-01-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103178-A1 | Modified, hydroxy-substituted aromatic structures having cytoprotective activity | ESR2, BAD, GPX4 | ESR1 12/4885ESR2 1/4885MEN1 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.